NVCR
NovoCure Limited
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$17.71
+0.40%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.8x
Market Cap
$2.06B
MomentumView details →
1D Return
+0.40%
YTD Return
+35.73%
RSI (14)
52.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.8x
Market Cap
$2.06B
RSI (14)
52.6
MomentumView details →
1D Return
+0.40%
YTD Return
+35.73%
SummaryUpdated Jun 1, 2026
NovoCure Limited (NASDAQ:NVCR) is a Jersey-incorporated oncology company founded in 2000 that has developed a novel cancer treatment technology called Tumor Treating Fields (TTFields). The company went public in 2015 and has since established itself as a pioneer in delivering electric field therapy for solid tumor cancers. NovoCure operates globally with commercial presence in the United States, Europe, Japan, and other international markets, focusing on bringing its unique non-invasive treatment modality to cancer patients worldwide.
Similar companies
Latest newsMore news →
Oncology company Novocure disclosed a cybersecurity incident involving unauthorized access to its information systems in mid-August, which exposed internal records of more than 1,400 U.S. patients.3d agoNovoCure Ltd elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, and Frank Leonard as directors, effective June 3, 2026.92d ago